146 related articles for article (PubMed ID: 20686472)
1. A case of hereditary hemorrhagic telangiectasia associated with Crohn's disease successfully treated with infliximab.
Papa A; Felice C; Marzo M; Guidi L
Am J Gastroenterol; 2010 Aug; 105(8):1904. PubMed ID: 20686472
[No Abstract] [Full Text] [Related]
2. The prevalence of malnutrition and the evolution of nutritional status in patients with moderate to severe forms of Crohn's disease treated with Infliximab.
Vadan R; Gheorghe LS; Constantinescu A; Gheorghe C
Clin Nutr; 2011 Feb; 30(1):86-91. PubMed ID: 20719413
[TBL] [Abstract][Full Text] [Related]
3. Inflixmab as a possible treatment for the hemorrhagic type of Crohn's disease.
Tsujikawa T; Nezu R; Andoh A; Saotome T; Araki Y; Ishizuka Y; Sasaki M; Koyama S; Fujiyama Y
J Gastroenterol; 2004; 39(3):284-7. PubMed ID: 15065007
[TBL] [Abstract][Full Text] [Related]
4. Infliximab in the management of the extra-intestinal manifestations of Crohn's disease.
Lawrance IC
J Gastroenterol Hepatol; 2004 Nov; 19(11):1332-3. PubMed ID: 15482549
[No Abstract] [Full Text] [Related]
5. Anti-tumor necrosis factor alpha monoclonal antibody (infliximab) for the treatment of Pyoderma gangrenosum associated with Crohn's disease.
Zaccagna A; Bertone A; Puiatti P; Picciotto F; Sprujevnik T; Santucci R; Rossini FP
Eur J Dermatol; 2003; 13(3):258-60. PubMed ID: 12804985
[TBL] [Abstract][Full Text] [Related]
6. Infliximab in Crohn's disease-associated toxic megacolon.
van Geenen EJ; Sachar DB
J Clin Gastroenterol; 2012 Apr; 46(4):321-3. PubMed ID: 21857531
[TBL] [Abstract][Full Text] [Related]
7. [Indications and results of infliximab in Crohn's disease].
Karoui S; Boubaker J; Filali A
Tunis Med; 2004 Dec; 82(12):1057-63. PubMed ID: 15822505
[TBL] [Abstract][Full Text] [Related]
8. The real cost of pediatric Crohn's disease: the role of infliximab in the treatment of pediatric IBD.
Kay M; Wyllie R
Am J Gastroenterol; 2003 Apr; 98(4):717-20. PubMed ID: 12738445
[No Abstract] [Full Text] [Related]
9. Crohn's-associated chronic recurrent multifocal osteomyelitis responsive to infliximab.
Carpenter E; Jackson MA; Friesen CA; Scarbrough M; Roberts CC
J Pediatr; 2004 Apr; 144(4):541-4. PubMed ID: 15069408
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcome of non-fistulizing (ulcers, stricture) perianal Crohn's disease in patients treated with infliximab.
Bouguen G; Trouilloud I; Siproudhis L; Oussalah A; Bigard MA; Bretagne JF; Peyrin-Biroulet L
Aliment Pharmacol Ther; 2009 Oct; 30(7):749-56. PubMed ID: 19583709
[TBL] [Abstract][Full Text] [Related]
11. Infliximab and the bone in Crohn's disease.
Kunisaki R; Chaki O; Taguchi T; Sugiyama T; Sugita A
Aliment Pharmacol Ther; 2005 Mar; 21(6):789-90. PubMed ID: 15771766
[No Abstract] [Full Text] [Related]
12. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. A BALANCING VIEW: lifetime channeling of infliximab for crohn's disease.
Hanauer SB
Am J Gastroenterol; 2005 Jul; 100(7):1438-9. PubMed ID: 15984961
[No Abstract] [Full Text] [Related]
13. Evidence for the clinical use of infliximab in Crohn's disease.
Turner SM; Probert CS
Rom J Gastroenterol; 2003 Mar; 12(1):2-5. PubMed ID: 12673372
[No Abstract] [Full Text] [Related]
14. [Infliximab in the treatment of Crohn's disease -- a practical approach. Infliximab and chronic Crohn's disease--Consensus statement of the Working Group on Chronic Inflammatory Crohn's Diseases of the OGGH].
Tilg H; Knoflach P; Petritsch W; Vogelsang H; Reinisch W;
Z Gastroenterol; 2004 Oct; 42(10):1256-63. PubMed ID: 15508068
[No Abstract] [Full Text] [Related]
15. [Pneumocystis pneumonia during infliximab treatment for active Crohn's colitis].
Minnee RC; Stokkers P; Riemens SC; Hommes DW
Ned Tijdschr Geneeskd; 2005 Oct; 149(41):2290-5. PubMed ID: 16240855
[TBL] [Abstract][Full Text] [Related]
16. Severe lower gastrointestinal bleeding in Crohn's disease: successful control with infliximab.
Belaiche J; Louis E
Am J Gastroenterol; 2002 Dec; 97(12):3210-1. PubMed ID: 12492221
[No Abstract] [Full Text] [Related]
17. Infliximab (Remicade), a new biological treatment for Crohn's disease.
D'Haens GR
Ital J Gastroenterol Hepatol; 1999; 31(6):519-20. PubMed ID: 10575573
[TBL] [Abstract][Full Text] [Related]
18. Guidelines for treatment with infliximab for Crohn's disease.
Hommes DW; Oldenburg B; van Bodegraven AA; van Hogezand RA; de Jong DJ; Romberg-Camps MJ; van der Woude J; Dijkstra G;
Neth J Med; 2006; 64(7):219-29. PubMed ID: 16929083
[TBL] [Abstract][Full Text] [Related]
19. Long-term partial remission of autoimmune thrombocytopenia in a patient treated with the anti-tumor necrosis factor-alpha antibody infliximab for refractory fistulizing Crohn's disease.
de Rossi TM; Krauss N; Voll RE; Nägel A; Weidenhiller M; Konturek PC; Hahn EG; Raithel M
Digestion; 2008; 78(4):195-200. PubMed ID: 19122456
[TBL] [Abstract][Full Text] [Related]
20. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated?
Domènech E; Hinojosa J; Nos P; Garcia-Planella E; Cabré E; Bernal I; Gassull MA
Aliment Pharmacol Ther; 2005 Dec; 22(11-12):1107-13. PubMed ID: 16305724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
